Studies on the pharmacokinetics and metabolism of a γ-secretase inhibitor BMS-299897, and exploratory investigation of CYP enzyme induction

References

• Anderson JJ, Holtz G, Baskin PP, Turner M, Rowe B, Wang B, Kounnas MZ, Lamb BT, Barten D, Felsenstein K, McDonald I, Srinivasan K, Munoz B, Wagner SL. (2005). Reduction of β-amyloid concentrations in vivo by the γ-secretase inhibitors BMS-289948 and BMS-299897. Biochem Pharmacol 69:689–98.
   PubMed Web of Science ®Google Scholar
• Arendt RM, Greenblatt DJ, deJong RH, Bonin JD, Abernethy DR, Ehrenberg BL, Giles HG, Sellers EM, Shader RI. (1983). In vitro correlates of benzodiazepine cerebrospinal fluid uptake, pharmacodynamic action and peripheral distribution. J Pharmacol Exp Ther 227:98–106.
   PubMedGoogle Scholar
• Barten DM, Albright CF. (2008). Therapeutic strategies for Alzheimer’s disease. Mol Neurobiol 37:171–86.
   PubMed Web of Science ®Google Scholar
• Barten DM, Guss VL, Corsa JA, Loo A, Hansel SB, Zheng M, Munoz B, Srinivasan K, Wang B, Robertson BJ, Polson CT, Wang J, Roberts SB, Hendrick JP, Anderson JJ, Loy JK, Denton R, Verdoorn TA, Smith DW, Felsenstein KM. (2005). Dynamics of β-amyloid reductions in brain, cerebrospinal fluid, and plasma of β-amyloid precursor protein transgenic mice treated with a γ-secretase inhibitor. J Pharmacol Exp Ther 312:635–43.
   PubMed Web of Science ®Google Scholar
• Bigotte L, Olsson Y. (1984). Cytotoxic effects of adriamycin on the central nervous system of the mouse — cytofluorescence and electron-microscopic observations after various modes of administration. Acta Neurologica Scandinavica Supplementum 100:55–67.
   PubMedGoogle Scholar
• Dickson AJ, Pogson CI. (1977). The metabolic integrity of hepatocytes in sustained incubations. FEBS Lett 83:27–32.
   PubMed Web of Science ®Google Scholar
• Evin G, Sernee MF, Masters CL. (2006). Inhibition of γ-secretase as a therapeutic intervention for Alzheimer’s disease: prospects, limitations and strategies. CNS Drugs 20:351–72.
   PubMed Web of Science ®Google Scholar
• Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, Quinn JF, Sherzai A, Sowell BB, Aisen PS, Thal LJ. (2008). Phase 2 safety trial targeting amyloid β production with a γ-secretase inhibitor in Alzheimer disease. Arc h Neurol 65:1031–8.
   PubMed Web of Science ®Google Scholar
• Hardy J, Selkoe DJ. (2002). The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297:353–6.
   PubMed Web of Science ®Google Scholar
• Hewitt NJ, Lechón MJG, Houston JB, Hallifax D, Brown HS, Maurel P, Kenna JG, Gustavsson L, Lohmann C, Skonberg C, Guillouzo A, Tuschl G, Li AP, LeCluyse E, Groothins GM, Hengstler JG. (2007). Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab Rev 39:159–234.
   PubMed Web of Science ®Google Scholar
• Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G. (1996). Correlative memory deficits, Abeta elevation and amyloid plaques in transgenic mice. Science 274(5284):99–102.
   PubMedGoogle Scholar
• Kato M, Chiba K, Horikawa M, Sugiyama Y. (2005). The quantitative prediction of in vivo enzyme-induction caused by drug exposure from in vitro information on human hepatocytes. Drug Metab Pharmacokinet 20:236–43.
   PubMedGoogle Scholar
• Kato M, Tachibana T, Ito K, Sugiyama Y. (2003). Evaluation of methods for predicting drug–drug interactions by Monte Carlo simulation. Drug Metab Pharmacokinet 18:121–7.
   PubMedGoogle Scholar
• Kliewer SA. (2003). The nuclear pregnane X receptor regulates xenobiotic detoxification. J Nutr 133(Suppl.):2444S–7S.
   Google Scholar
• Lin JH. (2006). CYP induction-mediated drug interactions: in vitro assessment and clinical implications. Pharmaceut Res 23:1089–16.
   PubMed Web of Science ®Google Scholar
• Lin JH. (2008). CSF as a surrogate for assessing CNS exposure: as industrial perspective. Curr Drug Metab 9:46–59.
   PubMed Web of Science ®Google Scholar
• Lundkvist J, Näslund J. (2007). γ-Secretase: a complex target for Alzheimer’s disease. Curr Opin Pharmacol 7:112–18.
   PubMedGoogle Scholar
• Luo G, Guenthner T, Gan L-S, Humphreys WG. (2004). CYP3A4 induction by xenobiotics: biochemistry, experimental methods and impact on drug discovery and development. Curr Drug Metab 5:483–505.
   PubMed Web of Science ®Google Scholar
• Morris DL, Davila JC. (1996). Analysis of rat cytochrome P450 isoenzymes expression using semi-quantitative reverse transcriptase-polymerase chain reaction (RT-PCR). Biochem Pharmacol 52:781–92.
   PubMed Web of Science ®Google Scholar
• Ohe T, Sato M, Tanaka S, Fujino N, Hata M, Shibata Y, Kanatani A, Fukami T, Yamazaki M, Chiba M, Ishii Y. (2003). Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid/plasma concentration ratio. Drug Metab Disposit 31:1251–4.
   PubMed Web of Science ®Google Scholar
• Olinga P, Elferink MGL, Draaisma AL, Merema MT, Castell JV, Pérez G, Groothuis GMM. (2008). Coordinated induction of drug transporters and phase I and II metabolism in human liver slices. Eur J Pharm Sci 33:380–9.
   PubMed Web of Science ®Google Scholar
• Page RA, Stowell KM, Hardman MJ, Kitson, KE. (1992). The assessment of viability in isolated rat hepatocytes. Analyt Biochem 206:171–5.
   Google Scholar
• Ripp SL, Mills JB, Fahmi OA, Trevena KA, Liras JL, Maurer TS, de Morais SM. (2006). Use of immortalized human hepatocytes to predict the magnitude of clinical drug–drug interactions caused by CYP3A4 induction. Drug Metab Disposit 34:1742–8.
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Smit JJM, Van Tellingen O, Beijnen JH, Wagenaar E, Van Deemter L, Mol CAAM, Van der Valk MA, Robanus-Maandag EC, te Riele HPJ, Berns AJM, Borst P. (1994). Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood–brain barrier and to increased sensitivity to drugs. Cell 77:491–502.
   PubMed Web of Science ®Google Scholar
• Siemers ER, Quinn JF, Kaye J, Farlow MR, Porsteinsson A, Tariot P, Zoulnouni P, Galvin JE, Holtzman DM, Knopman DS, Satterwhite J, Gonzales C, Dean RA, May PC. (2006). Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer’s disease. Neurology 66:602–4.
   PubMed Web of Science ®Google Scholar
• Sinz M, Kim S, Zhu Z, Chen T, Anthony M, Dickinson K, Rodrigues AD. (2006). Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Curr Drug Metab 7:375–88.
   PubMed Web of Science ®Google Scholar
• Smith DW, Munoz B, Srinivasan K, Bergstrom CP, Chatuvedula PV, Deshpande MS, Keavy DJ, Lau WY, Parker MF, Sloan CP, Wallace OB, Wang HH. (2000). Novel sulfonamide compounds and uses thereof, in US0004560. Merck & Co., Inc.; Bristol-Myers Squibb.
   Google Scholar
• United States Food and Drug Administration (USFDA). (2006). Guidance for industry: Drug interaction studies — study design, data analysis, and implications for dosing and labeling. Washington, DC: USFDA.
   Google Scholar
• Zhang D, Hanson R, Roongta V, Dischino DD, Gao Q, Sloan CP, Polson C, Keavy D, Zheng M, Mitroka J, Yeola S. (2006). In vitro and in vivo metabolism of a gamma-secretase inhibitor BMS-299897 and generation of active metabolites in milligram quantities with a microbial bioreactor. Curr Drug Metab 7:883–96.
   PubMedGoogle Scholar
• Zhou J, Zhang J, Xie W. (2005). Xenobiotic nuclear receptor-mediated regulation of UDP-glucuronosyltransferases. Curr Drug Metab 6:289–98.
   PubMed Web of Science ®Google Scholar